share_log

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A：修正後委託徵集材料
美股SEC公告 ·  08/20 12:52

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics，Inc.宣佈將於2024年9月3日上午10點(美國東部時間)舉行2024年股東年會。會議將通過現場音頻網絡直播的方式進行。議程包括幾個重要提案，如選舉兩名II類董事Gerald W. McLaughlin和Laura E. Benjamin，批准Wolf&Company，P.C.擔任2024年12月31日結束的財政年度的獨立核數師以及修改公司的《章程》以減少授權股份和普通股。此外，提議效果股票拆分，批准修改2021年股權激勵計劃，限制某些高級管理人員的責任以及必要時定期召開會議以徵求額外的代理也在議程中。董事會建議投票支持所有提案。會議還將討論其他事宜，這些事項可以在年度股東大會或其任何續展、延遲或推遲中正當地出現。
Allarity Therapeutics，Inc.宣佈將於2024年9月3日上午10點(美國東部時間)舉行2024年股東年會。會議將通過現場音頻網絡直播的方式進行。議程包括幾個重要提案，如選舉兩名II類董事Gerald W. McLaughlin和Laura E. Benjamin，批准Wolf&Company，P.C.擔任2024年12月31日結束的財政年度的獨立核數師以及修改公司的《章程》以減少授權股份和普通股。此外，提議效果股票拆分，批准修改2021年股權激勵計劃，限制某些高級管理人員的責任以及必要時定期召開會議以徵求額外的代理也在議程中。董事會建議投票支持所有提案。會議還將討論其他事宜，這些事項可以在年度股東大會或其任何續展、延遲或推遲中正當地出現。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間